Hannah Fry
Known title: VP, ControllerCIK: 0001938146
Associated companies
Transaction History
| TARA | ▼ Sell | Tax Withholding | 1,457 | $10K | 1/26/2026 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 2,132 | $12K | 1/20/2026 | View on chart |
| TARA | ▲ Buy | Grant | 9,500 | $0 | 1/16/2026 | View on chart |
| TARA | ▲ Buy | Grant | 9,500 | $0 | 1/24/2025 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 2,130 | $10K | 1/21/2025 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 394 | $2K | 1/3/2025 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 904 | $2K | 1/19/2024 | View on chart |
| TARA | ▲ Buy | Grant | 8,000 | $0 | 1/19/2024 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 324 | $703 | 1/3/2024 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 10,075 | $26K | 7/17/2023 | View on chart |
| TARA | ▲ Buy | Grant | 5,900 | $0 | 1/19/2023 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 361 | $1K | 1/3/2023 | View on chart |
| TARA | ▲ Buy | Grant | 25,000 | $0 | 7/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Protara Completes THRIVE-3 Trial Enrollment
Protara Therapeutics has finished enrolling patients in the Phase 2b dose confirmation phase of its THRIVE-3 registrational trial for IV Choline Chloride. This milestone marks a significant step in the development process for the company's lead product. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding the upcoming trial results.
Protara Completes THRIVE-3 Trial Enrollment. Protara Therapeutics has finished enrolling patients in the Phase 2b dose confirmation phase of its THRIVE-3 registrational trial for IV Choline Chloride. This milestone marks a significant step in the development process for the company's lead product. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding the upcoming trial results.